Prelude Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $330K | Sell |
5,253
-1,527
| -23% | -$122K | 0.03% | 672 |
|
|
2025
Q4 | $646K | Sell |
6,780
-34,830
| -84% | -$3.41M | 0.05% | 440 |
|
|
2025
Q3 | $4.06M | Buy |
+41,610
| New | +$4.31M | 0.32% | 56 |
|
|
2025
Q2 | – | Sell |
-7,731
| Closed | -$780K | – | 1030 |
|
|
2025
Q1 | $780K | Sell |
7,731
-5,060
| -40% | -$510K | 0.06% | 371 |
|
|
2024
Q4 | $1.14M | Buy |
+12,791
| New | +$1.13M | 0.07% | 348 |
|
|
2024
Q3 | – | Sell |
-4,357
| Closed | -$336K | – | 1291 |
|
|
2024
Q2 | $336K | Buy |
+4,357
| New | +$319K | 0.02% | 743 |
|
|
2023
Q1 | – | Sell |
-20,881
| Closed | -$966K | – | 1201 |
|
|
2022
Q4 | $966K | Buy |
+20,881
| New | +$904K | 0.05% | 391 |
|
|
2021
Q3 | – | Sell |
-35,151
| Closed | -$1.5M | – | 1762 |
|
|
2021
Q2 | $1.5M | Buy |
+35,151
| New | +$1.48M | 0.04% | 413 |
|
|
2021
Q1 | – | Sell |
-24,795
| Closed | -$891K | – | 1548 |
|
|
2020
Q4 | $891K | Buy |
24,795
+7,489
| +43% | +$270K | 0.02% | 511 |
|
|
2020
Q3 | $661K | Sell |
17,306
-41,933
| -71% | -$1.62M | 0.03% | 365 |
|
|
2020
Q2 | $2.08M | Buy |
59,239
+59,174
| +91,037% | +$2.13M | 0.11% | 159 |
|
|
2020
Q1 | $2K | Sell |
65
-39,240
| -100% | -$1.53M | ﹤0.01% | 1302 |
|
|
2019
Q4 | $1.78M | Sell |
39,305
-1,719
| -4% | -$71.9K | 0.07% | 245 |
|
|
2019
Q3 | $1.67M | Buy |
41,024
+19,348
| +89% | +$820K | 0.08% | 219 |
|
|
2019
Q2 | $932K | Buy |
21,676
+2,042
| +10% | +$78.5K | 0.05% | 358 |
|
|
2019
Q1 | $754K | Sell |
19,634
-33,266
| -63% | -$1.27M | 0.04% | 401 |
|
|
2018
Q4 | $1.87M | Buy |
52,900
+28,358
| +116% | +$1.03M | 0.13% | 186 |
|
|
2018
Q3 | $945K | Sell |
24,542
-9,044
| -27% | -$316K | 0.05% | 385 |
|
|
2018
Q2 | $1.1M | Sell |
33,586
-52,549
| -61% | -$1.58M | 0.07% | 308 |
|
|
2018
Q1 | $2.35M | Buy |
86,135
+51,534
| +149% | +$1.4M | 0.17% | 96 |
|
|
2017
Q4 | $858K | Sell |
34,601
-11,939
| -26% | -$329K | 0.07% | 286 |
|
|
2017
Q3 | $1.36M | Buy |
+46,540
| New | +$1.29M | 0.12% | 183 |
|
|
2016
Q4 | – | Sell |
-45,364
| Closed | -$1.08M | – | 1557 |
|
|
2016
Q3 | $1.08M | Buy |
45,364
+13,732
| +43% | +$328K | 0.11% | 199 |
|
|
2016
Q2 | $739K | Sell |
31,632
-6,397
| -17% | -$138K | 0.1% | 226 |
|
|
2016
Q1 | $715K | Buy |
38,029
+16,501
| +77% | +$290K | 0.1% | 227 |
|
|
2015
Q4 | $397K | Buy |
+21,528
| New | +$386K | 0.06% | 332 |
|
|
2015
Q2 | – | Sell |
-27,764
| Closed | -$493K | – | 1719 |
|
|
2015
Q1 | $493K | Buy |
27,764
+2,569
| +10% | +$40.6K | 0.07% | 343 |
|
|
2014
Q4 | $334K | Buy |
+25,195
| New | +$322K | 0.05% | 456 |
|
|
2014
Q1 | – | Sell |
-7,255
| Closed | -$87K | – | 1872 |
|
|
2013
Q4 | $87K | Buy |
+7,255
| New | +$85.7K | 0.01% | 908 |
|
|
2013
Q3 | – | Sell |
-9,900
| Closed | -$107K | – | 1712 |
|
|
2013
Q2 | $92K | Buy |
+9,900
| New | +$84K | 0.02% | 675 |
|
Other funds holding BSX
VCM
VPM
Prelude Capital Management's BSX Position: Q1 2026 in Review
Prelude Capital Management reduced its Boston Scientific (BSX) stake by 23% in Q1 2026, selling an estimated $122K and leaving 5,253 shares worth $330K. The position accounts for 0.03% of the portfolio, ranked #672.
Prelude Capital Management first reported a position in BSX in Q2 2013 and has held it in 30 quarters since. The position peaked at $4.06M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Prelude Capital Management held 5,253 shares of Boston Scientific worth $330K as of Q1 2026.
- Prelude Capital Management sold 1,527 Boston Scientific shares in Q1 2026, an estimated $122K.
- Boston Scientific made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #672 holding.
- Prelude Capital Management first reported a position in Boston Scientific in Q2 2013 and has held it in 30 quarters since.
- Prelude Capital Management's Boston Scientific position peaked at $4.06M in Q3 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.